Tags

Type your tag names separated by a space and hit enter

Levodopa in the treatment of Parkinson's disease.
Neurology. 2000; 55(11 Suppl 4):S2-7; discussion S8-12.Neur

Abstract

Levodopa is the most effective drug available for the symptomatic treatment of Parkinson's disease (PD) and is the gold standard with which other therapies must be compared. Levodopa improves most parkinsonian symptoms and is associated with an apparent decrease in mortality rate. However levodopa usage is also associated with both acute and chronic side effects which compromise treatment. Levodopa is metabolized by both decarboxylase and catechol-O-methyl transferase enzymes. It is routinely administered in combination with a decarboxylase inhibitor to prevent the peripheral accumulation of dopamine and associated side effects such as nausea and vomiting. More recent studies suggest that combination of levodopa with an inhibitor of catechol-O-methyl transferase prolongs the duration of effect of the drug and can prolong the duration of motor response in fluctuating patients. This article will review the safety and efficacy of levodopa treatment.

Authors+Show Affiliations

University of Miami School of Medicine, FL 33136, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11147506

Citation

Koller, W C.. "Levodopa in the Treatment of Parkinson's Disease." Neurology, vol. 55, no. 11 Suppl 4, 2000, pp. S2-7; discussion S8-12.
Koller WC. Levodopa in the treatment of Parkinson's disease. Neurology. 2000;55(11 Suppl 4):S2-7; discussion S8-12.
Koller, W. C. (2000). Levodopa in the treatment of Parkinson's disease. Neurology, 55(11 Suppl 4), S2-7; discussion S8-12.
Koller WC. Levodopa in the Treatment of Parkinson's Disease. Neurology. 2000;55(11 Suppl 4):S2-7; discussion S8-12. PubMed PMID: 11147506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levodopa in the treatment of Parkinson's disease. A1 - Koller,W C, PY - 2001/1/9/pubmed PY - 2001/2/28/medline PY - 2001/1/9/entrez SP - S2-7; discussion S8-12 JF - Neurology JO - Neurology VL - 55 IS - 11 Suppl 4 N2 - Levodopa is the most effective drug available for the symptomatic treatment of Parkinson's disease (PD) and is the gold standard with which other therapies must be compared. Levodopa improves most parkinsonian symptoms and is associated with an apparent decrease in mortality rate. However levodopa usage is also associated with both acute and chronic side effects which compromise treatment. Levodopa is metabolized by both decarboxylase and catechol-O-methyl transferase enzymes. It is routinely administered in combination with a decarboxylase inhibitor to prevent the peripheral accumulation of dopamine and associated side effects such as nausea and vomiting. More recent studies suggest that combination of levodopa with an inhibitor of catechol-O-methyl transferase prolongs the duration of effect of the drug and can prolong the duration of motor response in fluctuating patients. This article will review the safety and efficacy of levodopa treatment. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/11147506/Levodopa_in_the_treatment_of_Parkinson's_disease_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=11147506.ui DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.